Entrada's ENTR-601-45 Shows Favorable Safety and Dystrophin Increase in DMD Cohort 1
TRDA is trading near its 52-week low of $4.83 (4.1% above the low).
Summary
Entrada reported positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 in Duchenne muscular dystrophy. The 5 mg/kg dose met primary safety and tolerability objectives, with a 0.10% mean increase in dystrophin and 0.15% mean increase in exon skipping versus baseline. No hypomagnesemia or renal safety concerns were noted. Cohort 2 enrollment is complete and data at 10 mg/kg is expected in H1 2027. The company also highlighted an IDMC recommendation to proceed to 18 mg/kg in a separate study, supporting dose escalation to 15 mg/kg in Cohort 3. This is the first clinical efficacy signal for the program and validates the EEV platform's ability to deliver oligonucleotides. The stock trades near its 52-week low, so positive data could drive a re-rating.
At the time of this announcement, TRDA was trading at $5.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $189.2M. The 52-week trading range was $4.83 to $16.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.